<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>7(12)</volume><submitter>Tartof SY</submitter><pubmed_abstract>&lt;h4>Importance&lt;/h4>Clinical trials have demonstrated high vaccine efficacy (VE) against lower respiratory tract disease (LRTD) but enrolled a smaller proportion of persons aged 75 years or older and those with comorbidities than seen in highest-risk populations in clinical practice settings. Additionally, VE against respiratory syncytial virus (RSV)-related hospitalizations and emergency department (ED) visits is not yet fully described.&lt;h4>Objective&lt;/h4>To estimate Respiratory Syncytial Virus Prefusion F (RSVpreF) effectiveness in older adults.&lt;h4>Design, setting, and participants&lt;/h4>This was a retrospective case-control study with a test negative design. Cases were adults aged 60 years or older with hospitalizations or ED visits at Kaiser Permanente of Southern California for LRTD from </pubmed_abstract><journal>JAMA network open</journal><pagination>e2450832</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11645642</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Estimated Vaccine Effectiveness for Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease.</pubmed_title><pmcid>PMC11645642</pmcid><pubmed_authors>Chia B</pubmed_authors><pubmed_authors>Slezak J</pubmed_authors><pubmed_authors>Spence BC</pubmed_authors><pubmed_authors>Kapadia B</pubmed_authors><pubmed_authors>Aliabadi N</pubmed_authors><pubmed_authors>Liu Q</pubmed_authors><pubmed_authors>Tartof SY</pubmed_authors><pubmed_authors>Chilson E</pubmed_authors><pubmed_authors>Begier E</pubmed_authors><pubmed_authors>Aragones M</pubmed_authors><pubmed_authors>Dutro M</pubmed_authors><pubmed_authors>Davis GS</pubmed_authors><pubmed_authors>Gessner BD</pubmed_authors><pubmed_authors>Stern JA</pubmed_authors><pubmed_authors>Gonzalez E</pubmed_authors><pubmed_authors>Goodwin G</pubmed_authors><pubmed_authors>Lewnard JA</pubmed_authors><pubmed_authors>Shaw S</pubmed_authors><pubmed_authors>Welsh S</pubmed_authors><pubmed_authors>Hong V</pubmed_authors><pubmed_authors>Jodar L</pubmed_authors><pubmed_authors>Hubler R</pubmed_authors><pubmed_authors>Ackerson B</pubmed_authors></additional><is_claimable>false</is_claimable><name>Estimated Vaccine Effectiveness for Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease.</name><description>&lt;h4>Importance&lt;/h4>Clinical trials have demonstrated high vaccine efficacy (VE) against lower respiratory tract disease (LRTD) but enrolled a smaller proportion of persons aged 75 years or older and those with comorbidities than seen in highest-risk populations in clinical practice settings. Additionally, VE against respiratory syncytial virus (RSV)-related hospitalizations and emergency department (ED) visits is not yet fully described.&lt;h4>Objective&lt;/h4>To estimate Respiratory Syncytial Virus Prefusion F (RSVpreF) effectiveness in older adults.&lt;h4>Design, setting, and participants&lt;/h4>This was a retrospective case-control study with a test negative design. Cases were adults aged 60 years or older with hospitalizations or ED visits at Kaiser Permanente of Southern California for LRTD from </description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Dec</publication><modification>2026-07-15T01:44:36.139Z</modification><creation>2025-04-04T02:30:29.895Z</creation></dates><accession>S-EPMC11645642</accession><cross_references><pubmed>39671195</pubmed><doi>10.1001/jamanetworkopen.2024.50832</doi></cross_references></HashMap>